{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:49:59Z","timestamp":1785199799208,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n          <jats:p>\n            <jats:italic>Background.<\/jats:italic> Carboplatin and paclitaxel (CT) is one of the standard chemotherapy regimens used in various tumor types. Preclinical models have suggested that selinexor, a first-in-class oral potent selective inhibitor of nuclear export Exportin-1, and CT exerts antitumor activity in multiple malignancies. <jats:italic>Methods.<\/jats:italic> This was a single-center, multi-arm phase Ib study utilizing a \u201cbasket type\u201d expansion. CT and selinexor was employed as one of the 13 parallel arms. Advanced relapsed\/refractory solid tumors following standard therapy or where the addition of selinexor to standard regimens deemed appropriate, were eligible. <jats:italic>Results.<\/jats:italic> Of 13 patients treated, 12 patients were evaluable for response. The most common cancers were breast <jats:italic>(n<\/jats:italic>\u2009=\u2009<jats:italic>4),<\/jats:italic> esophageal <jats:italic>(n<\/jats:italic>\u2009=\u2009<jats:italic>2),<\/jats:italic> ovarian <jats:italic>(n<\/jats:italic>\u2009=\u2009<jats:italic>2)<\/jats:italic> and non-small cell lung cancers <jats:italic>(n<\/jats:italic>\u2009=\u2009<jats:italic>2).<\/jats:italic> All 13 patients had at least one treatment-related adverse events (TRAEs) and the most common were neutropenia (85%), leukopenia (85%), thrombocytopenia (85%), anemia (69%), nausea (54%), vomiting (46%), and fatigue (46%). One patient at 60\u00a0mg QW experienced DLT with grade 3 nausea and vomiting lasting 3\u00a0days. Unconfirmed partial response (uPR) was observed in 3 patients; one patient each with esophageal, breast, and ovarian cancer. One patient with esophageal adenocarcinoma had confirmed PR, however, was discontinued from the study due to clinical progression. Five patients achieved stable disease (SD). Disease control rate was 8%. Majority of patients (77%), including two patients who had uPR, had prior exposure to carboplatin and\/or paclitaxel. Time-to-treatment failure (TTF) ranged from 1 to 153\u00a0weeks. <jats:italic>Conclusion.<\/jats:italic> The RP2D of selinexor was 60\u00a0mg QW in combination with CT. The combination conferred viable clinical activity with durable objective responses which should further be explored in tumor types for which CT is used as standard of care. <jats:italic>Trial information.<\/jats:italic> ClinicalTrials.gov Identifier: NCT02419495. Sponsor(s): Karyopharm Therapeutics. (Trial registration: NCT02419495. Registered 14 April 2015, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02419495\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02419495<\/jats:ext-link>).<\/jats:p>","DOI":"10.1007\/s10637-021-01188-1","type":"journal-article","created":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T12:02:41Z","timestamp":1632571361000},"page":"290-299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1518-1097","authenticated-orcid":false,"given":"Kyaw Z.","family":"Thein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Karp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolia","family":"Tsimberidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Sulovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatin","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Den\u00e1i R.","family":"Milton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Janku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lacey","family":"McQuinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettzy A.","family":"Stephen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rivka","family":"Colen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett W.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina A.","family":"Piha-Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,25]]},"reference":[{"issue":"6657","key":"1188_CR1","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/36894","volume":"390","author":"M Fukuda","year":"1997","unstructured":"Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M, Yanagida M, Nishida E (1997) CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 390(6657):308\u2013311. https:\/\/doi.org\/10.1038\/36894","journal-title":"Nature"},{"issue":"18","key":"1188_CR2","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1091\/mbc.E12-01-0045","volume":"23","author":"D Xu","year":"2012","unstructured":"Xu D, Grishin NV, Chook YM (2012) NESdb: a database of NES-containing CRM1 cargoes. Mol Biol Cell 23(18):3673\u20133676. https:\/\/doi.org\/10.1091\/mbc.E12-01-0045","journal-title":"Mol Biol Cell"},{"issue":"2","key":"1188_CR3","first-page":"137","volume":"3","author":"KT Nguyen","year":"2012","unstructured":"Nguyen KT, Holloway MP, Altura RA (2012) The CRM1 nuclear export protein in normal development and disease. Int J Biochem Mol Biol 3(2):137\u2013151","journal-title":"Int J Biochem Mol Biol"},{"issue":"8","key":"1188_CR4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.bcp.2011.12.016","volume":"83","author":"JG Turner","year":"2012","unstructured":"Turner JG, Dawson J, Sullivan DM (2012) Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 83(8):1021\u20131032. https:\/\/doi.org\/10.1016\/j.bcp.2011.12.016","journal-title":"Biochem Pharmacol"},{"key":"1188_CR5","doi-asserted-by":"publisher","unstructured":"Benkova K, Mihalyova J, Hajek R, Jelinek T (2020) Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers. Blood Rev 100758.\u00a0https:\/\/doi.org\/10.1016\/j.blre.2020.100758","DOI":"10.1016\/j.blre.2020.100758"},{"issue":"14","key":"1188_CR6","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1158\/1078-0432.Ccr-14-1953","volume":"21","author":"T Miyake","year":"2015","unstructured":"Miyake T, Pradeep S, Wu SY, Rupaimoole R, Zand B, Wen Y, Gharpure KM, Nagaraja AS, Hu W, Cho MS, Dalton HJ, Previs RA, Taylor ML, Hisamatsu T, Kang Y, Liu T, Shacham S, McCauley D, Hawke DH, Wiktorowicz JE, Coleman RL, Sood AK (2015) XPO1\/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clin Cancer Res 21(14):3286\u20133297. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-1953","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1188_CR7","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1182\/blood-2014-10-607648","volume":"125","author":"P Ranganathan","year":"2015","unstructured":"Ranganathan P, Yu X, Santhanam R, Hofstetter J, Walker A, Walsh K, Bhatnagar B, Klisovic R, Vasu S, Phelps MA, Devine S, Shacham S, Kauffman M, Marcucci G, Blum W, Garzon R (2015) Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. Blood 125(17):2689\u20132692. https:\/\/doi.org\/10.1182\/blood-2014-10-607648","journal-title":"Blood"},{"issue":"6","key":"1188_CR8","doi-asserted-by":"publisher","first-page":"E315","DOI":"10.25011\/cim.v32i6.10668","volume":"32","author":"WY Huang","year":"2009","unstructured":"Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH, Sun YJ (2009) Prognostic value of CRM1 in pancreas cancer. Clin Invest Med 32(6):E315","journal-title":"Clin Invest Med"},{"issue":"8","key":"1188_CR9","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/cncr.23354","volume":"112","author":"A Noske","year":"2008","unstructured":"Noske A, Weichert W, Niesporek S, Roske A, Buckendahl AC, Koch I, Sehouli J, Dietel M, Denkert C (2008) Expression of the nuclear export protein chromosomal region maintenance\/exportin 1\/Xpo1 is a prognostic factor in human ovarian cancer. Cancer 112(8):1733\u20131743. https:\/\/doi.org\/10.1002\/cncr.23354","journal-title":"Cancer"},{"key":"1188_CR10","doi-asserted-by":"publisher","unstructured":"Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C (2009) Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 65 (1):153\u2013159; discussion 159\u2013160.\u00a0https:\/\/doi.org\/10.1227\/01.Neu.0000348550.47441.4b","DOI":"10.1227\/01.Neu.0000348550.47441.4b"},{"issue":"1","key":"1188_CR11","first-page":"229","volume":"21","author":"Y Yao","year":"2009","unstructured":"Yao Y, Dong Y, Lin F, Zhao H, Shen Z, Chen P, Sun YJ, Tang LN, Zheng SE (2009) The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep 21(1):229\u2013235","journal-title":"Oncol Rep"},{"key":"1188_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-014-0078-0","volume":"7","author":"K Parikh","year":"2014","unstructured":"Parikh K, Cang S, Sekhri A, Liu D (2014) Selective inhibitors of nuclear export (SINE)\u2013a novel class of anti-cancer agents. J Hematol Oncol 7:78. https:\/\/doi.org\/10.1186\/s13045-014-0078-0","journal-title":"J Hematol Oncol"},{"key":"1188_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.semcancer.2014.03.002","volume":"27","author":"HY Fung","year":"2014","unstructured":"Fung HY, Chook YM (2014) Atomic basis of CRM1-cargo recognition, release and inhibition. Semin Cancer Biol 27:52\u201361. https:\/\/doi.org\/10.1016\/j.semcancer.2014.03.002","journal-title":"Semin Cancer Biol"},{"key":"1188_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.semcancer.2014.04.005","volume":"27","author":"WT Senapedis","year":"2014","unstructured":"Senapedis WT, Baloglu E, Landesman Y (2014) Clinical translation of nuclear export inhibitors in cancer. Semin Cancer Biol 27:74\u201386. https:\/\/doi.org\/10.1016\/j.semcancer.2014.04.005","journal-title":"Semin Cancer Biol"},{"issue":"56","key":"1188_CR15","doi-asserted-by":"publisher","first-page":"30773","DOI":"10.18632\/oncotarget.25637","volume":"9","author":"T Kashyap","year":"2018","unstructured":"Kashyap T, Argueta C, Unger T, Klebanov B, Debler S, Senapedis W, Crochiere ML, Lee MS, Kauffman M, Shacham S, Landesman Y (2018) Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents. Oncotarget 9(56):30773\u201330786. https:\/\/doi.org\/10.18632\/oncotarget.25637","journal-title":"Oncotarget"},{"issue":"1","key":"1188_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13058-017-0878-6","volume":"19","author":"NP Arango","year":"2017","unstructured":"Arango NP, Yuca E, Zhao M, Evans KW, Scott S, Kim C, Gonzalez-Angulo AM, Janku F, Ueno NT, Tripathy D, Akcakanat A, Naing A, Meric-Bernstam F (2017) Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Res 19(1):93. https:\/\/doi.org\/10.1186\/s13058-017-0878-6","journal-title":"Breast Cancer Res"},{"issue":"8","key":"1188_CR17","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1158\/1535-7163.Mct-17-1303","volume":"17","author":"A Wahba","year":"2018","unstructured":"Wahba A, Rath BH, O\u2019Neill JW, Camphausen K, Tofilon PJ (2018) The XPO1 Inhibitor Selinexor Inhibits Translation and Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and In Vivo. Mol Cancer Ther 17(8):1717\u20131726. https:\/\/doi.org\/10.1158\/1535-7163.Mct-17-1303","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"1188_CR18","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1158\/1078-0432.Ccr-15-0978","volume":"22","author":"I Ferreiro-Neira","year":"2016","unstructured":"Ferreiro-Neira I, Torres NE, Liesenfeld LF, Chan CH, Penson T, Landesman Y, Senapedis W, Shacham S, Hong TS, Cusack JC (2016) XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer. Clin Cancer Res 22(7):1663\u20131673. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-0978","journal-title":"Clin Cancer Res"},{"key":"1188_CR19","doi-asserted-by":"publisher","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2):228\u2013247.\u00a0https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"1188_CR20","doi-asserted-by":"publisher","unstructured":"Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD (2010) Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR American Journal of Roentgenology 195 (2):281\u2013289. https:\/\/doi.org\/10.2214\/ajr.09.4110","DOI":"10.2214\/ajr.09.4110"},{"issue":"6b","key":"1188_CR21","doi-asserted-by":"publisher","first-page":"E25","DOI":"10.1111\/bju.12589","volume":"114","author":"G Sonpavde","year":"2014","unstructured":"Sonpavde G, Pond GR, Armstrong AJ, Galsky MD, Leopold L, Wood BA, Wang SL, Paolini J, Chen I, Chow-Maneval E, Mooney DJ, Lechuga M, Smith MR, Michaelson MD (2014) Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. BJU Int 114(6b):E25-e31. https:\/\/doi.org\/10.1111\/bju.12589","journal-title":"BJU Int"},{"issue":"2","key":"1188_CR22","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.molcel.2011.11.022","volume":"45","author":"L Golomb","year":"2012","unstructured":"Golomb L, Bublik DR, Wilder S, Nevo R, Kiss V, Grabusic K, Volarevic S, Oren M (2012) Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. Mol Cell 45(2):222\u2013232. https:\/\/doi.org\/10.1016\/j.molcel.2011.11.022","journal-title":"Mol Cell"},{"key":"1188_CR23","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.bbagrm.2011.05.017","volume":"7","author":"PJ van der Watt","year":"1809","unstructured":"van der Watt PJ (1809) Leaner VD (2011) The nuclear exporter, Crm1, is regulated by NFY and Sp1 in cancer cells and repressed by p53 in response to DNA damage. Biochim Biophys Acta 7:316\u2013326. https:\/\/doi.org\/10.1016\/j.bbagrm.2011.05.017","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"1188_CR24","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1634\/theoncologist.2019-0231","volume":"24","author":"M Shafique","year":"2019","unstructured":"Shafique M, Ismail-Khan R, Extermann M, Sullivan D, Goodridge D, Boulware D, Hogue D, Soliman H, Khong H, Han HS (2019) A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer. Oncologist 24(7):887-e416. https:\/\/doi.org\/10.1634\/theoncologist.2019-0231","journal-title":"Oncologist"},{"issue":"2","key":"1188_CR25","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ygyno.2019.11.012","volume":"156","author":"IB Vergote","year":"2020","unstructured":"Vergote IB, Lund B, Peen U, Umajuridze Z, Mau-Sorensen M, Kranich A, Van Nieuwenhuysen E, Haslund C, Nottrup T, Han SN, Concin N, Unger TJ, Chai Y, Au N, Rashal T, Joshi A, Crochiere M, Landesman Y, Shah J, Shacham S, Kauffman M, Mirza MR (2020) Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies. Gynecol Oncol 156(2):308\u2013314. https:\/\/doi.org\/10.1016\/j.ygyno.2019.11.012","journal-title":"Gynecol Oncol"},{"issue":"26","key":"1188_CR26","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1200\/jco.2016.67.6346","volume":"34","author":"MM Gounder","year":"2016","unstructured":"Gounder MM, Zer A, Tap WD, Salah S, Dickson MA, Gupta AA, Keohan ML, Loong HH, D\u2019Angelo SP, Baker S, Condy M, Nyquist-Schultz K, Tanner L, Erinjeri JP, Jasmine FH, Friedlander S, Carlson R, Unger TJ, Saint-Martin JR, Rashal T, Ellis J, Kauffman M, Shacham S, Schwartz GK, Abdul Razak AR (2016) Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. J Clin Oncol 34(26):3166\u20133174. https:\/\/doi.org\/10.1200\/jco.2016.67.6346","journal-title":"J Clin Oncol"},{"key":"1188_CR27","doi-asserted-by":"publisher","unstructured":"Lassman A, Wen P, van den Bent M, Plotkin S, Walenkamp A, Green A, Wang H, Li K, Liu Y, Xu H, Shah J, Kauffman M, Shacham S, Mau-Soerensen M (2020) CTNI-18. FINAL RESULTS OF A PHASE 2 STUDY OF EFFICACY, SAFETY AND INTRATUMORAL PHARMACOKINETICS (PK) OF SELINEXOR MONOTHERAPY IN RECURRENT GLIOBLASTOMA (rGBM). Neuro-Oncology 22 (Supplement_2):ii46-ii46.\u00a0https:\/\/doi.org\/10.1093\/neuonc\/noaa215.185","DOI":"10.1093\/neuonc\/noaa215.185"},{"issue":"34","key":"1188_CR28","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1200\/jco.2015.65.3949","volume":"34","author":"AR Abdul Razak","year":"2016","unstructured":"Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF, Unger TJ, Saint-Martin JR, Carlson R, Landesman Y, McCauley D, Rashal T, Lassen U, Kim R, Stayner LA, Mirza MR, Kauffman M, Shacham S, Mahipal A (2016) First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors. J Clin Oncol 34(34):4142\u20134150. https:\/\/doi.org\/10.1200\/jco.2015.65.3949","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s10637-021-01194-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000}},{"DOI":"10.1007\/s10637-024-01493-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000}}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01188-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01188-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01188-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T10:26:04Z","timestamp":1740047164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01188-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,25]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1188"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01188-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10637-024-01493-5","asserted-by":"object"},{"id-type":"doi","id":"10.1007\/s10637-021-01194-3","asserted-by":"object"}]},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,25]]},"assertion":[{"value":"8 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10637-024-01493-5","URL":"https:\/\/doi.org\/10.1007\/s10637-024-01493-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2021","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10637-021-01194-3","URL":"https:\/\/doi.org\/10.1007\/s10637-021-01194-3","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Applicable. This study was conducted in accordance with the U.S. Common Rule.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"The study protocol was approved by the Institutional Review Board or Independent Ethics Committee at MD Anderson Cancer Center and was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice, and all local and federal regulatory guidelines. (obtained).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study. (obtained).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Applicable (obtained).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Apostolia-Maria Tsimberidou has the following financial relationships to disclose: Research Funding (Institution): Immatics, Parker Institute for Cancer Immunotherapy, Tempus, OBI Pharma, EMD Serono, Baxalta, ONYX, Bayer, Boston Biomedical, Placon Therapeutics, Karus Therapeutics, and Tvardi Therapeutics. Consulting or Advisory Role: Covance, Genentech and Tempus.Aung Naing reports research funding from NCI; EMD Serono; MedImmune; Healios Onc. Nutrition; Atterocor; Amplimmune; ARMO BioSciences; Eli Lilly; Karyopharm Therapeutics; Incyte; Novartis; Regeneron; Merck; BMS; Pfizer, CytomX Therapeutics; Neon Therapeutics; Calithera Biosciences; TopAlliance Biosciences; Kymab; PsiOxus; Arcus Biosciences; NeoimmuneTech; ImmuneOncia; Surface Oncology. On advisory board of CytomX Therapeutics; Novartis and Genome & Company; OncoSec KEYNOTE-695; STCube. Travel and accommodation expense from ARMO BioSciences. Spouse Research funding: Immune Deficiency Foundation, Jeffery Modell Foundation and chao physician-scientist, and Baxalta. Advisory board: Takeda, CSL, Behring, Horizon, and Pharming.David S Hong reports Research\/Grant Funding: AbbVie, Adaptimmune,Aldi-Norte, Amgen, Astra Zeneca, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Eisai, Fate Therapeutics, Genentech, Genmab, GlaxoSmithKline, Ignyta, Infinity, Kite, Kyowa, Lilly, LOXO, Merck, MedImmune, Mirati, miRNA, Molecular Templates, Mologen, NCI-CTEP, Novartis, Pfizer, Seattle Genetics, Takeda, Turning Point Therapeutics. Travel, Accommodations, Expenses: Bayer, Genmab, AACR, ASCO, P.O.E.T, CCLO, SITC. Consulting or Advisory Role: Alpha Insights, Amgen, Axiom, Adaptimmune, Baxter, Bayer, eCancer, Genentech, GLG, Group H, Guidepoint, Infinity,Liberium, Medscape, Numab, Oncology Education Project Association, Pfizer, Prime Oncology, Takeda, Trieza, Therapeutics, WebMD. Other ownership interests: Molecular Match (Advisor), OncoResponse (Founder), Presagia Inc (Advisor).Filip Janku reports Grant\/Research Funding (Institutional): Novartis, Genentech, BioMed Valley Discoveries, Plexxikon, Deciphera, Piqur, Symphogen, Bayer, FujiFilm Corporation and Upsher-Smith Laboratories, Astex, Asana, Astellas, Agios, Proximagen, Bristol-Myers Squibb. Scientific Advisory Board: Deciphera, IFM Therapeutics, Synlogic, Guardant Health, Ideaya, PureTech Health. Paid Consultant: Trovagene, Immunomet, Jazz Pharmaceuticals, Sotio. Ownership Interests: Trovagene.Funda Meric-Bernstam reports Consulting: Aduro BioTech Inc., Alkermes, AstraZeneca, DebioPharm, eFFECTOR Therapeutics, F. Hoffman-La Roche Ltd., Genentech Inc., IBM Watson, Jackson Laboratory, Kolon Life Science, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Samsung Bioepis, Seattle Genetics Inc., Tyra Biosciences, Xencor, Zymeworks. Advisory Committee: Immunomedics, Inflection Biosciences, Mersana Therapeutics, Puma Biotechnology Inc., Seattle Genetics, Silverback Therapeutics, Spectrum Pharmaceuticals, Zentalis. Sponsored Research: Aileron Therapeutics, Inc. AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd., Debiopharm International, eFFECTOR Therapeutics, Genentech Inc., Guardant Health Inc., Millennium Pharmaceuticals Inc., Novartis, Puma Biotechnology Inc., Taiho Pharmaceutical Co. Honoraria: Chugai Biopharmaceuticals, Mayo Clinic, Rutgers Cancer Institute of New Jersey. Other (Travel Related): Beth Israel Deaconess Medical Center.Sarina A. Piha-Paul receives Research\/Grant Funding through the institution from the following sources: AbbVie, Inc.; ABM Therapeutics, Inc.; Acepodia, Inc; Alkermes; Aminex Therapeutics; Amphivena Therapeutics, Inc.; BioMarin Pharmaceutical, Inc; Boehringer Ingelheim; Bristol Myers Squib; Cerulean Pharma, Inc.; Chugai Pharmaceutical Co., Ltd; Curis, Inc.; Daiichi Sankyo; Eli Lilly; ENB Therapeutics; Five Prime Therapeutics; Gene Quantum; Genmab A\/S; GlaxoSmithKline; Helix BioPharma Corp.; Incyte Corp.; Jacobio Pharmaceuticals Co., Ltd.; Medimmune, LLC.; Medivation, Inc.; Merck Sharp and Dohme Corp.; Novartis Pharmaceuticals; Pieris Pharmaceuticals, Inc.; Pfizer; Principia Biopharma, Inc.; Puma Biotechnology, Inc.; Rapt Therapeutics, Inc.; Seattle Genetics; Silverback Therapeutics; Taiho Oncology; Tesaro, Inc.; TransThera Bio; NCI\/NIH; P30CA016672 \u2013 Core Grant (CCSG Shared Resources).Siqing Fu reports clinical trial research funding paid to the institution from Eli Lilly, during the conduct of the study; and clinical trial research funding paid to the institution from AstraZeneca, Abbisko, Anaeropharma Science, Arrien Pharmaceuticals, BeiGene, BioAtla, LLC, Boehringer Ingelheim, Eli Lilly, Hookipa Biotech GmBH, Huya Bioscience International, IMV, Inc., Innovent Biologics, Co., Ltd., Lyvgen Biopharm, Co., Ltd., MacroGenics, Medivir AB, Millennium Pharmaceuticals, Inc., Nerviano Medical Sciences, NeuPharma, Inc., NIH\/NCI, Novartis, OncoMed, Parexel International, LLC, Sellas Life Sciences Group, Soricimed Biopharma, Inc., Tolero Pharmaceuticals, all outside the submitted work.Timothy A. Yap reports research support (to institution) from Artios, AstraZeneca, Bayer, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, GlaxoSmithKline, Genentech, ImmuneSensor, Ipsen, Jounce, Karyopharm, Kyowa, Merck, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Sanofi, Scholar Rock, Seattle Genetics, Tesaro, and Vertex Pharmaceuticals, and consultancy fees from Almac, Aduro, AstraZeneca, Atrin, Axiom, Bayer, Bristol-Myers Squibb, Calithera, Clovis, Cybrexa, EMD Serono, F-Star, Guidepoint, Ignyta, I-Mab, Janssen, Merck, Pfizer, Repare, Roche, Rubius, Schrodinger, Seattle Genetics, Varian and Zai Labs outside of the submitted work.Jatin Shah is an employee of and stockholder of Karyopharm. All remaining authors have declared no conflicts of interest.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of potential conflicts of interest"}}]}}